Founded in January 2012 by physician Herriot Tabuteau, Axsome Therapeutics is a New York biopharmaceutical company focused on central nervous system conditions with limited treatment options. Its work centers on developing therapies intended to give patients and physicians new approaches where existing care falls short.
FDA Breakthrough Therapy Designation
Compliance program
FDA Orphan Drug Designation
Compliance program
Supernus Pharmaceuticals, IncFounded by Jack A. Khattar in 2005, Supernus Pharmaceuticals is a Rockville biopharmaceutical company that develops and commercializes medicines for central nervous system diseases. With more than 30 years of product-development expertise, it uses proprietary technologies and an active clinical pipeline to advance treatments in neurology and psychiatry, while marketing its medicines in the United States through specialty sales forces.ROCKVILLE, MD
Cognition Therapeutics, IncCognition Therapeutics is a clinical-stage neuroscience company developing oral medicines for age-related neurodegenerative diseases, with its research centered on zervimesine (CT1812), an investigational therapy intended to protect synapses from toxic protein oligomers. The company brings 20 years of mechanistic, translational, and clinical research to Alzheimer’s disease and dementia with Lewy bodies, where its once-daily small-molecule approach is being evaluated in Phase 2 studies. Headquartered in Purchase, New York, Cognition also uses clinical research and patient-caregiver engagement to address conditions that have historically received limited investment.PURCHASE, NY
Perception NeurosciencePerception Neuroscience is a New York City-based clinical-stage biopharmaceutical company developing PCN-101, an R-ketamine compound intended to provide faster-acting treatment options for serious psychiatric disorders. The company holds an exclusive license to intellectual property originating from research at Japan’s Chiba University and has advanced PCN-101 through Phase 1 studies and an FDA-cleared IND into Phase 2 clinical development. Perception is majority-owned by atai Life Sciences and partnered with Otsuka Pharmaceutical on development in Japan.New York, NY